The development of the electron probe microanalyzer (EPMA) in Japan in the early 1960s, when Prof. R. Castaing visited Japan, is briefly outlined. In 1955, a review article was published by Prof. G. Shinoda in Oyobutsuri, the most popular journal in Japan, in which the EPMA was introduced. In 1957, a research group at the University of Tokyo started to develop an EPMA with a Grant-in-Aid for Developmental Research. Their research results led to the funding of a 2-year Grant-in-Aid for Cooperative Research Project (April 1960 to March 1962), which was chaired by Prof. Y. Sakaki. Prof. G. Shinoda who became the chairman of that project in April of 1962 led that group for another year until March of 1963. It was just after the start of the project that Prof. R. Castaing visited Japan in September of 1960 as a representative of the French Mission Culturelle. This visit gave a great push forward for the commercial development of EPMA instruments in Japan. The first three commercial EPMA instruments from Hitachi, JEOL, and Akashi Ltds. were installed in Tohoku, Osaka, and Waseda Universities in 1962, 1963, and 1964, respectively. Photographs of those first commercial EPMA systems, together with a brief description of the activities of the cooperative research projects, are presented.
Download full-text PDF |
Source |
---|
J Hepatol
March 2014
Centre National de Référence de la Maladie de Wilson/Centre Hépato-Biliaire, Hôpital Paul Brousse, AP-HP, Villejuif, France; UMR 785, INSERM, France; UMR-S 785, Univ Paris-Sud, Villejuif, France; DHU Hepatinov, Villejuif, France.
Background & Aims: Liver transplantation (LT) is the therapeutic option for severe complications of Wilson's disease (WD). We aimed to report on the long-term outcome of WD patients following LT.
Methods: The medical records of 121 French patients transplanted for WD between 1985 and 2009 were reviewed retrospectively.
Open Respir Med J
March 2013
Pfizer Global Research and Development, Paris, France.
Introduction: This study was conducted to evaluate the efficacy of tigecycline (TGC) versus levofloxacin (LEV) in hospitalized patients with community-acquired pneumonia (CAP) using pooled data and to perform exploratory analyses of risk factors associated with poor outcome.
Materials And Methodology: Pooled analyses of 2 phase 3 studies in patients randomized to intravenous (IV) TGC (100 mg, then 50 mg q12h) or IV LEV (500 mg q24h or q12h). Clinical responses at test of cure visit for the clinically evaluable (CE) and clinical modified intention to treat populations were assessed for patients with risk factors including aged ≥65 years, prior antibiotic failure, bacteremia, multilobar disease, chronic obstructive pulmonary disease, alcohol abuse, altered mental status, hypoxemia, renal insufficiency, diabetes mellitus, white blood cell count >30 x 10(9)/L or <4 x 10(9)/L, CURB-65 score ≥2, Fine score category of III to V and at least 2 clinical instability criteria on physical examination.
The polymicrobial nature of complicated intra-abdominal infections makes these infections particularly challenging to treat. The initial selection of antimicrobial therapy is therefore extremely important. Inappropriate empiric antimicrobial therapy has been shown to delay clinical resolution, increase length of hospital stay, and increase the risk of mortality.
View Article and Find Full Text PDFMicrosc Microanal
March 2001
Department of Applied Physics, Osaka University, Suita, Osaka 565-0871, Japan.
The development of the electron probe microanalyzer (EPMA) in Japan in the early 1960s, when Prof. R. Castaing visited Japan, is briefly outlined.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!